(Q33733253)

29 July 2017

Correlations between dose, plasma concentrations, and antispastic action of tizanidine (Sirdalud). (English)

1 reference

29 July 2017

1 reference

Emre M

1

1 reference

29 July 2017

Leslie GC

2

1 reference

29 July 2017

Muir C

3

1 reference

29 July 2017

Part NJ

4

1 reference

29 July 2017

Pokorny R

5

1 reference

29 July 2017

Roberts RC

6

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 November 1994

1 reference

Journal of Neurology, Neurosurgery and Psychiatry

29 July 2017

1 reference

29 July 2017

57

1 reference

29 July 2017

1355-1359

1 reference

29 July 2017

11

1 reference

Double-blind comparison of single doses of DS103-282, baclofen and placebo for suppression of spasticity

29 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1073186

Antiparetic and antispastic effects induced by tizanidine in patients with spastic paresis.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1073186

Spinal interneurone depression by DS103-282.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1073186

Selective depression of synaptic transmission of spinal neurones in the cat by a new centrally acting muscle relaxant, 5-chloro-4-(2-imidazolin-2-yl-amino)-2, 1, 3-benzothiodazole (DS103-282)

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1073186

Tizanidine (DS103-282), a centrally acting muscle relaxant, selectively depresses excitation of feline dorsal horn neurones to noxious peripheral stimuli by an action at α2-adrenoceptors

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1073186

Treatment of spasticity with tizanidine in multiple sclerosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1073186

Descriptive data analysis: a concept between confirmatory and exploratory data analysis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1073186

Does the Wartenberg pendulum test differentiate quantitatively between spasticity and rigidity? A study in elderly stroke and Parkinsonian patients

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1073186

Pharmacodynamics and pharmacokinetics of the oral antispastic agent tizanidine in patients with spinal cord injury.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1073186

Tizanidine versus baclofen in the treatment of spasticity in multiple sclerosis patients

21 June 2018

1 reference

12 December 2020

Pendulousness of the legs as a diagnostic test

1 reference

12 December 2020

PRELIMINARY TRIAL OF CARISOPRODOL IN MULTIPLE SCLEROSIS

1 reference

12 December 2020

The pharmacology of 5-chloro-4-(2-imidazolin-2-yl-amino)-2,1,3-benzothiadiazole (DS 103-282), a novel myotonolytic agent

1 reference

12 December 2020

Pendulum testing of spasticity

1 reference

12 December 2020

Multi-centre, double-blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis

1 reference

12 December 2020

Identifiers

DOI

10.1136/JNNP.57.11.1355

1 reference

release_cycu3fevpvgonmvt4bpukg53oa

29 July 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/cycu3fevpvgonmvt4bpukg53oa

24 November 2022

mapped directly with Wikidata item

PMCID

1073186

1 reference

29 July 2017

1 reference